{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T10:44:47Z","timestamp":1785926687858,"version":"3.56.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,8,28]],"date-time":"2011-08-28T00:00:00Z","timestamp":1314489600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s11060-011-0686-2","type":"journal-article","created":{"date-parts":[[2011,8,27]],"date-time":"2011-08-27T13:51:18Z","timestamp":1314453078000},"page":"225-234","source":"Crossref","is-referenced-by-count":34,"title":["Novel approaches to treating leptomeningeal metastases"],"prefix":"10.1007","volume":"106","author":[{"given":"Jai","family":"Grewal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon Garzo","family":"Saria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Kesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,28]]},"reference":[{"key":"686_CR1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0733-8619(02)00032-4","volume":"21","author":"S Kesari","year":"2003","unstructured":"Kesari S, Batchelor TT (2003) Leptomeningeal metastases. Neurol Clin N Am 21:25\u201366","journal-title":"Neurol Clin N Am"},{"key":"686_CR2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(06)70443-4","volume":"5","author":"B Gleissner","year":"2006","unstructured":"Gleissner B, Chamberlain MC (2006) Neoplastic meningitis. Lancet Neurol 5:443\u2013452","journal-title":"Lancet Neurol"},{"key":"686_CR3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-009-9819-2","volume":"4","author":"MD Groves","year":"2009","unstructured":"Groves MD, Hess KR, Puduvalli VK et al (2009) Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol 4:229\u2013234","journal-title":"J Neurooncol"},{"key":"686_CR4","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1200\/JCO.1989.7.11.1701","volume":"7","author":"MS Mitchell","year":"1989","unstructured":"Mitchell MS (1989) Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol 7:1701\u20131709","journal-title":"J Clin Oncol"},{"key":"686_CR5","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.currproblcancer.2007.07.001","volume":"31","author":"WP O\u2019Meara","year":"2007","unstructured":"O\u2019Meara WP, Borkar SA, Stambuk HE et al (2007) Leptomeningeal metastasis. Curr Probl Cancer 31:372\u2013424","journal-title":"Curr Probl Cancer"},{"key":"686_CR6","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/archneur.1981.00510110056008","volume":"38","author":"WH Theodore","year":"1981","unstructured":"Theodore WH, Gendelman S (1981) Meningeal carcinomatosis. Arch Neurol 38:696\u2013699","journal-title":"Arch Neurol"},{"key":"686_CR7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/1097-0142(19820715)50:2<219::AID-CNCR2820500209>3.0.CO;2-7","volume":"50","author":"HY Yap","year":"1982","unstructured":"Yap HY, Yap BS, Rasmussen S et al (1982) Treatment for meningeal carcinomatosis in breast cancer. Cancer 50:219\u2013222","journal-title":"Cancer"},{"key":"686_CR8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/archneur.55.2.181","volume":"55","author":"M Jorda","year":"1998","unstructured":"Jorda M, Ganjei-Azar P, Nadji M (1998) Cytologic characteristics of meningeal carcinomatosis. Increased diagnostic accuracy using carcinoembryonic antigen and epithelial membrane antigen immunocytochemistry. Arch Neurol 55:181\u2013184","journal-title":"Arch Neurol"},{"key":"686_CR9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/B978-012088410-0\/50060-3","volume-title":"Handbook of brain tumor chemotherapy","author":"MC Chamberlain","year":"2006","unstructured":"Chamberlain MC (2006) CSF Disseminated primary brain tumors. In: Newton HB (ed) Handbook of brain tumor chemotherapy. Elsevier Science, San Diego, pp 316\u2013326"},{"key":"686_CR10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11060-004-8093-6","volume":"75","author":"IT Gavrilovic","year":"2005","unstructured":"Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75:5\u201314","journal-title":"J Neurooncol"},{"key":"686_CR11","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1212\/WNL.29.10.1369","volume":"29","author":"JP Glass","year":"1979","unstructured":"Glass JP, Melamed M, Chernik NL et al (1979) Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 29:1369\u20131375","journal-title":"Neurology"},{"key":"686_CR12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11060-007-9353-z","volume":"84","author":"B Gleissner","year":"2007","unstructured":"Gleissner B, Chamberlain MC (2007) Treatment of CNS dissemination in systemic lymphoma. J Neurooncol 84:107\u2013117","journal-title":"J Neurooncol"},{"key":"686_CR13","first-page":"108","volume":"1","author":"C Hatton","year":"2005","unstructured":"Hatton C (2005) Lymphomatous meningitis. Haematologica Rep 1:108\u2013109","journal-title":"Haematologica Rep"},{"key":"686_CR14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11910-008-0038-6","volume":"8","author":"MC Chamberlain","year":"2008","unstructured":"Chamberlain MC (2008) Neoplastic meningitis. Curr Neurol Neurosci Rep 8:249\u2013258","journal-title":"Curr Neurol Neurosci Rep"},{"key":"686_CR15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0090-3019(99)00186-X","volume":"53","author":"S Yoshida","year":"2000","unstructured":"Yoshida S, Morii K, Watanabe M et al (2000) Characteristic features of malignant lymphoma with central nervous system involvement. Surg Neurol 53:163\u2013167","journal-title":"Surg Neurol"},{"key":"686_CR16","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<733::AID-CNCR17>3.0.CO;2-Z","volume":"82","author":"MJ Glantz","year":"1998","unstructured":"Glantz MJ, Cole BF, Glantz LK et al (1998) Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 82:733\u2013739","journal-title":"Cancer"},{"key":"686_CR17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/003130299104774","volume":"31","author":"MS Ward","year":"1999","unstructured":"Ward MS (1999) The use of flow cytometry in the diagnosis and monitoring of malignant hematological disorders. Pathology 31:382\u2013392","journal-title":"Pathology"},{"key":"686_CR18","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s11095-005-6039-0","volume":"22","author":"CE Johanson","year":"2005","unstructured":"Johanson CE, Duncan JA, Stopa EG et al (2005) Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route. Pharm Res 22:1011\u20131037","journal-title":"Pharm Res"},{"key":"686_CR19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jns.2008.10.029","volume":"277","author":"Z Kobayashi","year":"2009","unstructured":"Kobayashi Z, Tsuchiya K, Machida A et al (2009) Metastatic CNS lymphoma presenting with periventricular dissemination\u2013MRI and neuropathological finding in an autopsy case. J Neurological Sci 277:109\u2013113","journal-title":"J Neurological Sci"},{"key":"686_CR20","first-page":"231","volume":"56","author":"S Levine","year":"1987","unstructured":"Levine S (1987) Choroid plexus: target for systemic disease and pathway to the brain. Lab Invest 56:231\u2013233","journal-title":"Lab Invest"},{"key":"686_CR21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0165-5728(93)90230-V","volume":"46","author":"MB Oldstone","year":"1993","unstructured":"Oldstone MB, Southern PJ (1993) Trafficking of activated cytotoxic T lymphocytes into the central nervous system: use of a transgenic model. J Neuroimmunol 46:25\u201331","journal-title":"J Neuroimmunol"},{"key":"686_CR22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11912-003-0082-y","volume":"5","author":"MD Groves","year":"2003","unstructured":"Groves MD (2003) The pathogenesis of neoplastic meningitis. Curr Oncol Rep 5:15\u201323","journal-title":"Curr Oncol Rep"},{"key":"686_CR23","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1158\/1078-0432.CCR-07-5125","volume":"14","author":"C Alix-Panabieres","year":"2008","unstructured":"Alix-Panabieres C, Riethdorf S, Pantel K (2008) Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res 14:5013\u20135021","journal-title":"Clin Cancer Res"},{"key":"686_CR24","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1200\/JCO.2008.16.3931","volume":"26","author":"M Kakarala","year":"2008","unstructured":"Kakarala M, Wicha MS (2008) Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 26:2813\u20132820","journal-title":"J Clin Oncol"},{"key":"686_CR25","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/jnci\/djn123","volume":"100","author":"X Li","year":"2008","unstructured":"Li X, Lewis MT, Huang J et al (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672\u2013679","journal-title":"J Natl Cancer Inst"},{"key":"686_CR26","first-page":"129","volume-title":"Cancer: principles and practice in oncology","author":"IJ Fidler","year":"2005","unstructured":"Fidler IJ, Langley RR, Kerbel RS et al (2005) Angiogenesis. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice in oncology. Lippincott Williams & Wilkins, New York, pp 129\u2013135"},{"key":"686_CR27","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<178::AID-CNCR25>3.0.CO;2-7","volume":"85","author":"A Kraft","year":"1999","unstructured":"Kraft A, Weindel K, Ochs A et al (1999) Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85:178\u2013187","journal-title":"Cancer"},{"key":"686_CR28","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1212\/WNL.54.8.1670","volume":"54","author":"G Stockhammer","year":"2000","unstructured":"Stockhammer G, Poewe W, Burgstaller S et al (2000) Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 54:1670\u20131676","journal-title":"Neurology"},{"key":"686_CR29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10585-008-9225-8","volume":"26","author":"S Goswami","year":"2009","unstructured":"Goswami S, Phillippar U, Sun D et al (2009) Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo. Clin Exp Metastasis 26:153\u2013159","journal-title":"Clin Exp Metastasis"},{"key":"686_CR30","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.3171\/foc.2006.21.5.2","volume":"21","author":"C Kadoch","year":"2006","unstructured":"Kadoch C, Treseler P, Rubenstein JL (2006) Molecular pathogenesis of primary central nervous system lymphoma. Neurosurg Focus 21:E1","journal-title":"Neurosurg Focus"},{"key":"686_CR31","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1158\/1541-7786.327.2.6","volume":"2","author":"B-C Lee","year":"2004","unstructured":"Lee B-C, Lee T-H, Avraham S et al (2004) Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1\u03b1 in breast cancer cell migration through human brain microvascular endothelial cells. Mol Cancer Res 2:327\u2013338","journal-title":"Mol Cancer Res"},{"key":"686_CR32","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/sj.bjc.6605055","volume":"100","author":"S Singh","year":"2009","unstructured":"Singh S, Nannuru KC, Sandanandam A et al (2009) CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer 100:1638\u20131646","journal-title":"Br J Cancer"},{"key":"686_CR33","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.devcel.2008.09.003","volume":"15","author":"U Philippar","year":"2008","unstructured":"Philippar U, Roussos ET, Oser M et al (2008) A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev Cell 15:813\u2013828","journal-title":"Dev Cell"},{"key":"686_CR34","doi-asserted-by":"crossref","first-page":"7022","DOI":"10.1158\/0008-5472.CAN-04-1449","volume":"64","author":"J Wyckoff","year":"2004","unstructured":"Wyckoff J, Wang W, Lin EY et al (2004) A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64:7022\u20137029","journal-title":"Cancer Res"},{"key":"686_CR35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1023\/A:1005926624303","volume":"38","author":"RJ Oostenbrugge Van","year":"1998","unstructured":"Van Oostenbrugge RJ, Hopman AHN, Ramaekers FCS et al (1998) In situ hybridization: a possible diagnostic aid in leptomeningeal metastasis. J Neurooncol 38:127\u2013133","journal-title":"J Neurooncol"},{"key":"686_CR36","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.2000.18.10.2053","volume":"18","author":"RJ Oostenbrugge Van","year":"2000","unstructured":"Van Oostenbrugge RJ, Hopman AHN, Arends JW et al (2000) Treatment of leptomeningeal metastasis evaluated by interphase cytogenetics. J Clin Oncol 18:2053\u20132058","journal-title":"J Clin Oncol"},{"key":"686_CR37","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jns.2006.05.044","volume":"247","author":"JM Baehring","year":"2006","unstructured":"Baehring JM, Hochberg FH, Betensky RA et al (2006) Immunoglobulin gene rearrangement analysis in cerebrospinal fluid of patients with lymphoproliferative processes. J Neurol Sci 247:208\u2013216","journal-title":"J Neurol Sci"},{"key":"686_CR38","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1212\/WNL.58.3.390","volume":"58","author":"B Gleissner","year":"2002","unstructured":"Gleissner B, Siehl J, Korfel A et al (2002) CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 58:390\u2013396","journal-title":"Neurology"},{"key":"686_CR39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11912-003-0084-9","volume":"5","author":"SL Berg","year":"2003","unstructured":"Berg SL, Chamberlain MC (2003) Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis. Curr Oncol Rep 5:29\u201340","journal-title":"Curr Oncol Rep"},{"key":"686_CR40","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/0-387-24199-X_8","volume":"125","author":"SL Berg","year":"2005","unstructured":"Berg SL, Chamberlain MC (2005) Current treatment of leptomeningeal metastases: systemic chemotherapy, intrathecal chemotherapy and symptom management. Cancer Treat Res 125:121\u2013146","journal-title":"Cancer Treat Res"},{"key":"686_CR41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11060-004-8100-y","volume":"75","author":"MC Chamberlain","year":"2005","unstructured":"Chamberlain MC, Nolan C, Abrey LE (2005) Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. J Neurooncol 75:71\u201383","journal-title":"J Neurooncol"},{"key":"686_CR42","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3171\/jns.1997.87.5.0694","volume":"87","author":"MC Chamberlain","year":"1997","unstructured":"Chamberlain MC, Kormanik PA, Barba D (1997) Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 87:694\u2013699","journal-title":"J Neurosurg"},{"key":"686_CR43","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1212\/WNL.44.8.1463","volume":"44","author":"T Siegal","year":"1994","unstructured":"Siegal T, Lossos A, Pfeffer MR (1994) Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 44:1463\u20131469","journal-title":"Neurology"},{"key":"686_CR44","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1002\/1097-0142(19950615)75:12<2919::AID-CNCR2820751220>3.0.CO;2-9","volume":"75","author":"MJ Glantz","year":"1995","unstructured":"Glantz MJ, Hall WA, Cole BF et al (1995) Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 75:2919\u20132931","journal-title":"Cancer"},{"issue":"12","key":"686_CR45","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1002\/1097-0142(19950615)75:12<2919::AID-CNCR2820751220>3.0.CO;2-9","volume":"75","author":"MJ Glantz","year":"1995","unstructured":"Glantz MJ, Hall WA, Cole BF et al (1995) Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 75(12):2919\u20132931","journal-title":"Cancer"},{"key":"686_CR46","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1212\/01.wnl.0000205135.85388.01","volume":"66","author":"MC Chamberlain","year":"2006","unstructured":"Chamberlain MC, Glantz M (2006) Ventriculoperitoneal shunt in patients with leptomeningeal metastases. Neurology 66:783","journal-title":"Neurology"},{"key":"686_CR47","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1212\/01.WNL.0000160396.69050.DC","volume":"10","author":"AM Omuro","year":"2005","unstructured":"Omuro AM, Lallana EC, Bilsky MH et al (2005) Ventriculoperitoneal shunt in patients with leptomeningeal metastases. Neurology 10:1625\u20131627","journal-title":"Neurology"},{"key":"686_CR48","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1227\/01.NEU.0000232655.78335.D5","volume":"59","author":"J Mocco","year":"2006","unstructured":"Mocco J, Tomey MI, Komotar RJ et al (2006) Ventriculoperitoneal shunting of idiopathic normal pressure hydrocephalus increases midbrain size: a potential mechanism for gait improvement. Neurosurgery 59:847\u2013851","journal-title":"Neurosurgery"},{"key":"686_CR49","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/jpm.2008.0227","volume":"12","author":"D Schiff","year":"2009","unstructured":"Schiff D, Kline C, Meltzer H et al (2009) Palliative venticuloperitoneal shunt in a pediatric patient with recurrent metastatic medulloblastoma. J Palliat Med 12:391\u2013393","journal-title":"J Palliat Med"},{"key":"686_CR50","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00000421-199808000-00010","volume":"21","author":"J Lokich","year":"1998","unstructured":"Lokich J, Levine H, Nasser I (1998) Malignancy-related hydrocephalus: clinical features and results of ventricular peritoneal shunt procedure in three patients. Am J Clin Oncol 21:366\u2013368","journal-title":"Am J Clin Oncol"},{"key":"686_CR51","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ygyno.2007.09.024","volume":"108","author":"Y Eralp","year":"2008","unstructured":"Eralp Y, Saip P, Aydin Z et al (2008) Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt. Gynecol Oncol 108:248\u2013250","journal-title":"Gynecol Oncol"},{"key":"686_CR52","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/BF00271892","volume":"5","author":"M Matsumae","year":"1989","unstructured":"Matsumae M, Sato O, Itoh K et al (1989) Quantification of cerebrospinal fluid shunt flow rates. Assessment of the programmable pressure valve. Childs Nerv Syst 5:356\u2013360","journal-title":"Childs Nerv Syst"},{"key":"686_CR53","first-page":"222","volume":"32","author":"M Chiafery","year":"2006","unstructured":"Chiafery M (2006) Care and management of the child with shunted hydrocephalus. Pediatr Nurs 32:222\u2013225","journal-title":"Pediatr Nurs"},{"key":"686_CR54","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.1999.17.10.3110","volume":"17","author":"MJ Glantz","year":"1999","unstructured":"Glantz MJ, LaFollette S, Jaeckle KA et al (1999) Randomized trial of a slow-release versus standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110\u20133116","journal-title":"J Clin Oncol"},{"key":"686_CR55","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/cncr.24204","volume":"115","author":"JA Garcia-Marco","year":"2009","unstructured":"Garcia-Marco JA, Panizo C, Garcia ES et al (2009) Efficacy and safely of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Cancer 115:1892\u20131898","journal-title":"Cancer"},{"key":"686_CR56","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nbt1137","volume":"23","author":"GP Adams","year":"2005","unstructured":"Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147\u20131157","journal-title":"Nat Biotechnol"},{"key":"686_CR57","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/ncponc1156","volume":"5","author":"DA Cameron","year":"2008","unstructured":"Cameron DA, Stein S (2008) Drug insight: intracellular inhibitors of HER2\u2014clinical development of lapatinib in breast cancer. Nat Clin Pract Oncol 5:512\u2013520","journal-title":"Nat Clin Pract Oncol"},{"key":"686_CR58","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","volume":"15","author":"NU Lin","year":"2009","unstructured":"Lin NU, Di\u00e9ras V, Paul D et al (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:1452\u20131459","journal-title":"Clin Cancer Res"},{"key":"686_CR59","doi-asserted-by":"crossref","unstructured":"Onishi H, Morisaki T, Nakafusa Y et al. (2011) Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2\/HER1-negative breast cancer. Int J Clin Oncol. doi: 10.1007\/s10147-011-0195-5","DOI":"10.1007\/s10147-011-0195-5"},{"key":"686_CR60","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129\u20132139","journal-title":"N Engl J Med"},{"key":"686_CR61","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497\u20131500","journal-title":"Science"},{"key":"686_CR62","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1200\/JCO.2008.18.7658","volume":"27","author":"A Inoue","year":"2009","unstructured":"Inoue A, Kobayashi K, Usui K et al (2009) First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27:1394\u20131400","journal-title":"J Clin Oncol"},{"key":"686_CR63","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/cncr.21033","volume":"103","author":"AM Omuro","year":"2005","unstructured":"Omuro AM, Kris MG, Miller VA et al (2005) High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 103:2344\u20132348","journal-title":"Cancer"},{"key":"686_CR64","unstructured":"Jackman DM, Kesari S, Cioffredi L et al. (2009) Phase I study of high dose gefitinib in patients with leptomeningeal metastases from EGFR-mutant non-small cell lung cancer. Presented at the 13th World Congress on Lung Cancer San Francisco, 31st July\u20134th August 2009; Poster P1.189"},{"key":"686_CR65","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.lungcan.2008.10.016","volume":"65","author":"HG Yi","year":"2009","unstructured":"Yi HG, Kim HJ, Kim YJ et al (2009) Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 65:80\u201384","journal-title":"Lung Cancer"},{"key":"686_CR66","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1200\/JCO.2006.06.6126","volume":"24","author":"DM Jackman","year":"2006","unstructured":"Jackman DM, Holmes A, Lindeman N et al (2006) Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 24:4517\u20134520","journal-title":"J Clin Oncol"},{"issue":"2","key":"686_CR67","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11060-010-0128-6","volume":"99","author":"JL Clarke","year":"2010","unstructured":"Clarke JL, Pao W, Wu N et al (2010) High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99(2):283\u2013286","journal-title":"J Neurooncol"},{"key":"686_CR68","doi-asserted-by":"crossref","unstructured":"Tetsumoto S, Osa A, Kijima T et al (2011) Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib. Int J Clin Oncol. doi: 10.1007\/s10147-011-0256-9","DOI":"10.1007\/s10147-011-0256-9"},{"key":"686_CR69","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12282-008-0056-x","volume":"16","author":"T Shigekawa","year":"2009","unstructured":"Shigekawa T, Takeuchi H, Misumi M et al (2009) Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report. Breast Cancer 16:88\u201392","journal-title":"Breast Cancer"},{"key":"686_CR70","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11060-007-9409-0","volume":"85","author":"M Ekenel","year":"2007","unstructured":"Ekenel M, Hormigo AM, Peak S et al (2007) Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 85:223\u2013227","journal-title":"J Neurooncol"},{"key":"686_CR71","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3816\/CBC.2006.n.028","volume":"7","author":"YL Tham","year":"2006","unstructured":"Tham YL, Hinckley L, Teh BS et al (2006) Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin Breast Cancer 7:164\u2013166","journal-title":"Clin Breast Cancer"},{"key":"686_CR72","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejim.2008.04.015","volume":"20","author":"S Paydas","year":"2009","unstructured":"Paydas S, Bicakci K, Yavuz S (2009) Dramatic response with capecitabine after cranial radiation to the brain parenchymal and leptomeningeal metastases from lung cancer. Eur J Intern Med 20:96\u201399","journal-title":"Eur J Intern Med"},{"key":"686_CR73","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/cncr.22127","volume":"107","author":"E Rivera","year":"2006","unstructured":"Rivera E, Meyers C, Groves M et al (2006) Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 107:1348\u20131354","journal-title":"Cancer"},{"key":"686_CR74","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(01)00622-2","volume":"3","author":"IJ Fidler","year":"2002","unstructured":"Fidler IJ, Yano S, Zhang RD et al (2002) The seed and soil hypothesis: vascularization and brain metastases. Lancet Oncol 3:53\u201357","journal-title":"Lancet Oncol"},{"key":"686_CR75","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3816\/CCC.2008.n.010","volume":"7","author":"A Bhaskara","year":"2008","unstructured":"Bhaskara A, Eng C (2008) Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases. Clin Colorectal Cancer 7:65\u201368","journal-title":"Clin Colorectal Cancer"},{"key":"686_CR76","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/B:CLIN.0000024761.00373.55","volume":"21","author":"LS Kim","year":"2004","unstructured":"Kim LS, Huang S, Lu W et al (2004) Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis 21:107\u2013118","journal-title":"Clin Exp Metastasis"},{"key":"686_CR77","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00165486","volume":"27","author":"JB Posner","year":"1996","unstructured":"Posner JB (1996) Brain metastases: 1995 a brief review. J Neurooncol 27:287\u2013293","journal-title":"J Neurooncol"},{"key":"686_CR78","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1200\/JCO.2006.10.3317","volume":"25","author":"GY Ku","year":"2007","unstructured":"Ku GY, Krol G, Ilson DH (2007) Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan. J Clin Oncol 25:e14\u2013e16","journal-title":"J Clin Oncol"},{"key":"686_CR79","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/00003495-200666060-00005","volume":"66","author":"RS Cvetkovic","year":"2006","unstructured":"Cvetkovic RS, Perry CM (2006) Rituximab: a review of its use in non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia. Drugs 66:791\u2013820","journal-title":"Drugs"},{"key":"686_CR80","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-0609.2006.00789.x","volume":"67","author":"R Marcus","year":"2007","unstructured":"Marcus R, Hagenbeek A (2007) The therapeutic use of rituximab in non-Hodgkin\u2019s lymphoma. Eur J Haematol Suppl 67:5\u201314","journal-title":"Eur J Haematol Suppl"},{"key":"686_CR81","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2006.09.7311","volume":"25","author":"JL Rubenstein","year":"2007","unstructured":"Rubenstein JL, Fridlyand J, Abrey L et al (2007) Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 25:1350\u20131355","journal-title":"J Clin Oncol"},{"key":"686_CR82","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-008-9707-1","volume":"91","author":"MC Chamberlain","year":"2009","unstructured":"Chamberlain MC, Johnston SK, Van Horn A et al (2009) Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J Neurooncol 91:271\u2013277","journal-title":"J Neurooncol"},{"key":"686_CR83","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2008.16.8021","volume":"27","author":"SH Bernstein","year":"2009","unstructured":"Bernstein SH, Unger JM, Leblanc M et al (2009) Natural history of CNS relapse in patients with aggressive non-Hodgkin\u2019s lymphoma: a 20-year follow-up analysis of SWOG 8516\u2014the southwest oncology group. J Clin Oncol 27:114\u2013119","journal-title":"J Clin Oncol"},{"key":"686_CR84","unstructured":"Canales M, Pe\u00f1arrubia MJ, Salar A et al. (2008) Efficacy and safety of intrathecal liposomal cytarabine injection given prophylactically in patients with high-risk diffuse large B-cell lymphoma: a report of 24 patients in Spain. Abstract Presented at: the 13th Congress of the European Hematology Association, Copenhagen, Denmark, 12\u201315 June"},{"key":"686_CR85","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/CCO.0b013e32830b829e","volume":"20","author":"HY Lim","year":"2008","unstructured":"Lim HY, Thiel E, Glantz MJ (2008) To protect and defend: central nervous system prophylaxis in patients with non-Hodkin\u2019s lymphoma. Curr Opin Oncol 20:495\u2013501","journal-title":"Curr Opin Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-011-0686-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-011-0686-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-011-0686-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T01:23:38Z","timestamp":1686273818000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-011-0686-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,28]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["686"],"URL":"https:\/\/doi.org\/10.1007\/s11060-011-0686-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,28]]}}}